Current treatments, such as C1-INH replacement, lanadelumab, and berotralstat, are effective in controlling HAE attacks but require frequent, lifelong administration and primarily address only symptoms rather than the underlying genetic defect[4,5,11]. This evidence concerns the gene SERPING1 and hereditary angioedema.